Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.61 | N/A | +6.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.61 | N/A | +6.11% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding EPS growth. However, they did not provide specific guidance for future revenue expectations.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts to enhance product offerings and market presence.
Supernus Pharmaceuticals reported a positive surprise in EPS, which contributed to a 3.77% increase in stock price. The lack of revenue data leaves some uncertainty, but the EPS beat indicates strong performance in that area. Investors may view the stock's rise as a sign of confidence in the company's future potential.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARRIOTT INTL INC NE Class A
Aug 5, 2019